Real-life results of urate-driven pharmacotherapy with three urate lowering drugs in gout: allopurinol, febuxostat and benzbromarone
Aim: This study aims to assess outcomes of gout patients from the treat to target (T2T) perspective at 6 months and 12 months while using urate lowering therapy (ULT): allopurinol, febuxostat, and/or benzbromarone. Methods: All gout patients visiting the Rheumatology department between 2015 to 2021...
Saved in:
Main Authors: | Ioana Hotea, Tanja Giesen, Antoaneta Comarniceanu, Monique Efde, Frits van Osch, Matthijs Janssen, Tim L. Jansen |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2023-08-01
|
Series: | Exploration of Musculoskeletal Diseases |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100714/100714.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
by: M. N. Chikina
Published: (2019-01-01) -
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?
by: Edward Roddy, et al.
Published: (2024-11-01) -
Impact of urate-lowering therapy on quality of life indicators in patients with gout
by: M. N. Chikina, et al.
Published: (2021-06-01) -
Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
by: J. Chen, et al.
Published: (2021-04-01) -
Is Urate-lowering therapy a prevention of first gout episode?
by: Michał Szczepański, et al.
Published: (2025-07-01)